| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1224772 | Journal of Pharmaceutical and Biomedical Analysis | 2006 | 4 Pages |
Some microplate-based direct assays with different fluorometric substrates have been developed, among which 7-benzyloxyquinoline (BOQ) has demonstrated the highest degree of selectivity for CYP3A subfamily. In our study, we firstly developed and validated an efficient, fast and cheap HPLC/spectrofluorometric analytical method to quantify 7-hydroxyquinoline (BOQ metabolite). Secondly, BOQ oxidation rate (1.95 ± 0.24 μM/mg protein/min) was compared to that of midazolam (MDZ) (1.4 ± 0.21 μM/mg protein/min), an other specific CYP3A probe. However, the difference did not reach statistically significance (test of Sign; p = 0.125, two tailed). Thirdly, the potential use of BOQ in other species than the rat (mouse, dog and monkey) was studied. The highest BOQ activity was observed in rat microsomes (3.75 μmol/mg protein/min) with lower P450 content (0.3 nmol/mg protein) compared to other species. Finally, the effect of CYP3A enzymes-selective inhibitor ketoconazole on the dealkylation of BOQ in control and dexamethasone (DM)-treated rat microsomes was studied. Ketoconazole inhibition potency was greater in control (IC50 ≈ 21.6 μM) compared to DM induced (IC50 ≈ 32.3 μM) microsomes. At concentrations greater than that considered to be enzyme-selective (e.g., 10–30 μM), ketoconazole inhibitory activity did not rise significantly, and at the maximal concentration tested (1000 μM) a nearly similar inhibition (76%) was observed than that at 50 μM concentration (68.2%).
